NEW YORK, December 25, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. SPPI, and certain officers. The class action, filed in the United States District Court for the Southern District of New York and registered at 22-cv-10677, is on behalf of a class consisting of all persons and entities that did not purchase or otherwise acquire the defendants

If you are a shareholder who purchased or otherwise acquired Affirm securities during the class action period, you have until February 3, 2023 to ask the court to appoint you as lead plaintiff in the class action. A copy of the complaint is available at www.pomerantzlaw.com. To discuss this promotion, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Individuals inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Spectrum purports to be a biopharmaceutical company focused on acquiring, developing and commercializing novel and targeted oncology therapies.

The Complaint alleges that the Defendants conducted a Phase 2 clinical trial called ZENITH20 prior to the Class Period. The ZENITH20 study was an ongoing, multi-center, multi-cohort-free, activity-estimating study to evaluate the antitumor efficacy, safety, and tolerability of poziotinib or “pozi” in patients with locally advanced or non-small metastatic cell lung cancer (“NSCLC”) harboring certain mutations (HER2 -exon 20 insertion mutations) and have previously been treated with standard care. Prior to the Class Period, the Company had a pre-NDA meeting with the FDA at which Spectrum confirmed to the FDA that data from Cohort 2 could serve as the basis for filing a New Drug Application (“NDA”). In cohort 2, the objective response rate (complete or partial response, which are a measure of whether…